AMRI Announces Executive Hire to Lead Active Pharmaceutical Ingredients Business

Jan 20, 2016, 08:45 ET from AMRI

ALBANY, N.Y., Jan. 20, 2016 /PRNewswire/ -- AMRI (NASDAQ:  AMRI) announced today that Dawn M. Von Rohr, will join AMRI as Sr. Vice President, API, effective January 25, 2016. Ms. Von Rohr will report to George Svokos, Chief Operating Officer, and will be a member of the executive team led by President and Chief Executive Officer, William Marth.  Ms. Von Rohr will have responsibility for setting and implementing the strategic direction for AMRI's growing Active Pharmaceutical Ingredient (API) business unit and for achieving the financial results of that business, AMRI's largest business unit.

"We are pleased to welcome Dawn to AMRI," said Mr. Svokos. "We are confident that she brings the expertise and dynamic leadership to define and drive the next phase of growth for the API business and that her abilities in successfully leading a global, commercial API business will enhance our customers' experience as we continue to provide them with the complex API products and services they need."

Ms. Von Rohr comes to AMRI from Mallinckrodt Pharmaceuticals, where she was Vice President and General Manager, Global APIs. In this role, she was part of the executive leadership team that set the direction and executed the successful spin-out of Mallinckrodt from Covidien, and she successfully led a business that met and exceeded profit targets each year. Ms. Von Rohr brings her strategic pricing, product rationalization and business building experience.

Ms. Von Rohr began her career within the Quality and Research & Development Department at Schering Plough and then began a 22-year career with Mallinckrodt Pharmaceuticals. With a technical and business education, she transitioned to Sales and Marketing holding increasing responsibilities including Business Manager, Director Technology and Business Development; Senior Global Business Director; and Vice President and General Manager. Dawn was an extended Board Member of the Drug, Chemical, and Associated Technologies (DCAT) Organization from 2013 to 2015.

Ms. Von Rohr has a Bachelor of Arts degree in Chemistry from Vanderbilt University, and a Master of Business Administration degree with a concentration in Marketing from Washington University in St. Louis.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations.

SOURCE AMRI



RELATED LINKS

http://www.amriglobal.com